Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Biohaven Ltd. ( (BHVN) ) just unveiled an update.
On November 12, 2025, Biohaven Ltd. entered into an underwriting agreement with J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC for a public offering of up to 26,833,334 common shares at $7.50 per share. The following day, the company successfully issued and sold the full amount, including additional shares, raising approximately $200 million in gross proceeds, which will impact its financial operations and market positioning.
The most recent analyst rating on (BHVN) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Biohaven Ltd. stock, see the BHVN Stock Forecast page.
Spark’s Take on BHVN Stock
According to Spark, TipRanks’ AI Analyst, BHVN is a Underperform.
Biohaven Ltd.’s overall stock score is low due to substantial financial challenges, including zero revenue and negative cash flow. Technical analysis indicates bearish momentum, and the valuation is unattractive due to a negative P/E ratio. However, the recent $600 million investment provides a positive outlook by supporting clinical developments. Despite this, the overall risks remain significant, making the stock a cautious investment.
To see Spark’s full report on BHVN stock, click here.
More about Biohaven Ltd.
Average Trading Volume: 3,225,095
Technical Sentiment Signal: Sell
Current Market Cap: $841.5M
See more insights into BHVN stock on TipRanks’ Stock Analysis page.